GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Talphera Inc (NAS:TLPH) » Definitions » Cyclically Adjusted PS Ratio

Talphera (Talphera) Cyclically Adjusted PS Ratio : 0.29 (As of May. 18, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Talphera Cyclically Adjusted PS Ratio?

As of today (2024-05-18), Talphera's current share price is $1.08. Talphera's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $3.76. Talphera's Cyclically Adjusted PS Ratio for today is 0.29.

The historical rank and industry rank for Talphera's Cyclically Adjusted PS Ratio or its related term are showing as below:

TLPH' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.08   Med: 5.41   Max: 14.72
Current: 0.31

During the past years, Talphera's highest Cyclically Adjusted PS Ratio was 14.72. The lowest was 0.08. And the median was 5.41.

TLPH's Cyclically Adjusted PS Ratio is ranked better than
91.01% of 745 companies
in the Drug Manufacturers industry
Industry Median: 2.17 vs TLPH: 0.31

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Talphera's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.015. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $3.76 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Talphera Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Talphera's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talphera Cyclically Adjusted PS Ratio Chart

Talphera Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.45 5.30 - - 0.20

Talphera Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.19 0.10 0.20

Competitive Comparison of Talphera's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Talphera's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Talphera's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Talphera's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Talphera's Cyclically Adjusted PS Ratio falls into.



Talphera Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Talphera's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.08/3.76
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Talphera's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Talphera's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.015/129.4194*129.4194
=0.015

Current CPI (Dec. 2023) = 129.4194.

Talphera Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.044 99.695 0.057
201406 0.032 100.560 0.041
201409 2.180 100.428 2.809
201412 0.102 99.070 0.133
201503 0.081 99.621 0.105
201506 0.868 100.684 1.116
201509 6.851 100.392 8.832
201512 0.774 99.792 1.004
201603 1.336 100.470 1.721
201606 2.000 101.688 2.545
201609 1.485 101.861 1.887
201612 2.839 101.863 3.607
201703 1.371 102.862 1.725
201706 1.172 103.349 1.468
201709 0.642 104.136 0.798
201712 0.294 104.011 0.366
201803 0.135 105.290 0.166
201806 0.316 106.317 0.385
201809 0.126 106.507 0.153
201812 0.173 105.998 0.211
201903 0.067 107.251 0.081
201906 0.239 108.070 0.286
201909 0.153 108.329 0.183
201912 0.119 108.420 0.142
202003 0.096 108.902 0.114
202006 0.725 108.767 0.863
202009 0.311 109.815 0.367
202012 0.160 109.897 0.188
202103 0.090 111.754 0.104
202106 0.074 114.631 0.084
202109 0.312 115.734 0.349
202112 0.000 117.630 0.000
202203 0.000 121.301 0.000
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000
202212 0.000 125.222 0.000
202303 0.000 127.348 0.000
202306 0.023 128.729 0.023
202309 0.007 129.860 0.007
202312 0.015 129.419 0.015

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Talphera  (NAS:TLPH) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Talphera Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Talphera's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Talphera (Talphera) Business Description

Traded in Other Exchanges
Address
25821 Industrial Boulevard, Suite 400, Hayward, CA, USA, 94545
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Its product portfolio includes Niyad that is a lyophilized formulation of nafamostat. It is also developing two pre-filled syringes, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe.
Executives
Vincent J. Angotti director, officer: Chief Executive Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Pamela P Palmer director, officer: Chief Medical Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Jill Marie Broadfoot director 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Marina Bozilenko director C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Adrian Adams director C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19355
Mark G Edwards director ALLOS THERAPEUTICS, INC., 11080 CIRCLEPOINT ROAD, SUITE 200, WESTMINSTER CO 80020
Raffi Asadorian officer: Chief Financial Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Lawrence G Hamel officer: Chief Development Officer C/O ACELRX PHARMACEUTICALS INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Badri N Dasu officer: Chief Engineering Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Mark A Wan director, 10 percent owner C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Three Arch Associates Iii Lp 10 percent owner C/O THREE ARCH PARTNERS, 3200 ALPINE ROAD, PORTOLA VALLEY CA 94028
Wilfred E Jaeger 10 percent owner C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Three Arch Partners Iii Lp 10 percent owner
Three Arch Partners Iv Lp 10 percent owner
Three Arch Associates Iv Lp 10 percent owner 3200 ALPINE ROAD, PORTOLA VALLEY CA 94028

Talphera (Talphera) Headlines

From GuruFocus